Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

Jennifer S. Carew(University of Arizona), Steffan T. Nawrocki(University of Arizona), Francis J. Giles(National University of Ireland)

Cancer Letters

May 7, 2008

10.1016/j.canlet.2008.03.037

Cited by 426

Related Papers

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

|Journal of Clinical Oncology|2005|951

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

|Clinical Cancer Research|2008|782

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

|Blood|2006|691

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

|Cancer|2006|607

Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance

|Blood|2007|485